Stanford University
Showing 91-100 of 302 Results
-
John Kerner
Professor of Pediatrics (Gastroenterology), Emeritus
Current Research and Scholarly InterestsI am interested in pediatric nutritional support and have experience evaluating new enteral and parenteral products especially for the neonate (I studied a "new" I.V. fat product for Abbott; I participated in a multicenter trial of a formula with fish oil in it for neonates with Mead Johnson and a multicenter trial of a new human milk fortifier for Wyeth).
-
Andrew Kesselman
Clinical Assistant Professor, Radiology
Current Research and Scholarly InterestsCurrently studying the role of interventional therapies in caval filtration, venous thromboembolism and primary and metastatic hepatic malignancies.
-
Terence Ketter
Professor of Psychiatry and Behavioral Sciences (Psychopharmacology), Emeritus
Current Research and Scholarly InterestsThe use of brain imaging methods for understanding the neurobiology of mood disorders and to target treatments for patients with bipolar disorders. Research in the use of novel medications and combinations of medications in the treatment of bipolar disorders. Research on the development and course of bipolar disorder in late adolescence and young adulthood, particularly in college students, and links between creativity, temperament, and mood disorders.
-
Kian Keyashian
Clinical Associate Professor, Medicine - Gastroenterology & Hepatology
BioThe management of inflammatory bowel disease continues to evolve, with the introduction of biologic and small molecule therapies and new goals of treatment, with an emphasis on healing the bowel. My career goal since my graduation from IBD fellowship in 2012 has been to improve the outcomes and quality of life of patients with inflammatory bowel disease. In line with these goals, my research has focused investigating new noninvasive diagnostic test, finding factors early in the disease course that might predict a more aggressive disease course and need for different therapies, and investigating new promising effective medications with less side effects.